DENVER — Rezpegaldesleukin improved the severity of hair loss among adults with severe and very severe alopecia areata, according to results from the phase 2b REZOLVE-AA study.
“This is a proof-of-concept study demonstrating a targeted treatment that can help patients with severe alopecia areata,” David Rosmarin, MD, chair of the department of dermatology, associate professor of dermatology and Kampen-Norins Scholar in Dermatology at Indiana University School of Medicine, told Healio. “The unique mechanism of stimulating regulatory T-cells is a potential therapy with a very favorable safety

NEW ORLEANS — In patients with type 2 diabetes and established CVD, tirzepatide conferred lower risk for cardiorenal adverse events compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial.
As Healio previously reported, in the main results of SURPASS-CVOT, risk for major adverse CV events was similar between the tirzepatide (Mounjaro, Eli Lilly) and dulaglutide (Trulicity, Eli Lilly) groups, but risk for all-cause mortality was 16% lower in the tirzepatide group. Healio | Cardiology Today Editorial Board Member Steven E. Nissen, MD, MACC, chief academic officer of

NEW ORLEANS — A combination of left ventricular support plus delayed percutaneous coronary intervention did not reduce infarct size compared with immediate PCI in patients with anterior STEMI without shock, researchers reported.
LV unloading with a transvalvular micro-axial flow pump (Impella CP, Johnson & Johnson MedTech) for 30 minutes before PCI lengthened time-to-procedure and was associated with more bleeding and vascular complications compared with immediate PCI alone, according to the STEMI Door to Unload (STEMI-DTU) trial presented at the American College of Cardiology Scientific

DENVER — The American Academy of Dermatology honored dermatologist and researcher Henry W. Lim, MD, FAAD, with the 2026 Gold Medal Award for more than 50 years of dedication and leadership in the specialty.
The award was presented during the opening ceremony at the American Academy of Dermatology Annual Meeting by President Susan C. Taylor, MD, FAAD.
Lim, currently president of the International League of Dermatological Societies (ILDS), is also senior vice president of academic programs at Henry Ford Health and past president of the AAD. A champion of inclusion within dermatology, Lim is a

NEW ORLEANS — In the HI-PEITHO trial, ultrasound-facilitated catheter-directed thrombolysis plus anticoagulation conferred better 30-day outcomes compared with anticoagulation alone in patients with acute intermediate-risk pulmonary embolism.
At the American College of Cardiology Scientific Session, researchers reported results from 544 adults (mean age, 58 years; 43% women; 15.8% self-identified as “non-white”; mean symptom duration, 3.7 days) who presented with intermediate-risk pulmonary embolism (PE) and two or more indicators of cardiorespiratory distress. Each patient was randomly

DENVER — Dermatologists must use “precise, clinically grounded language” when documenting gender-affirming care to ensure any procedures can withstand scrutiny in the current regulatory climate, according to a speaker.
More than 2.8 million youths and adults living in the United States identify as transgender, or 1% of those aged 13 years and older, Klint Peebles, MD, FAAD, a board-certified dermatologist with Kaiser Permanente Mid-Atlantic Permanente Medical Group in Washington, D.C., said during a presentation at the 22nd Annual Skin of Color Society Scientific Symposium. The race and

NEW ORLEANS — In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, researchers reported.
The CHAMPION-AF trial, presented at the American College of Cardiology Scientific Session and simultaneously published in The New England Journal of Medicine, randomly assigned 3,000 patients with AF (mean age, 71 years; 32% women; mean CHA2DS2-VASc score, 3.5) to receive device-based left atrial appendage (LAA) closure (Watchman FLX, Boston Scientific) or a

MIAMI — Innovation and technology are evolving to meet the need of “an aging population that needs our care now more than ever,” according to Matt Jensen, MBA.
“We just don’t have enough doctors to get to them,” he said during a presentation at Sunshine Eye & Retina. “We are facing a time when we need our optometrist friends in their craft to operate at the very tip-top of their training and licensure. We need ophthalmologists to operate at the very tip-top of their craft and licensure so we can get to the patients who need us most.”
Current financial challenges in ophthalmology include